Product Description
A fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor (IGF-1R) with potential antineoplastic activity. Cixutumumab selectively binds to membrane-bound IGF-1R, thereby preventing the binding of the natural ligand IGF-1 and the subsequent activation of PI3K/AKT signaling pathway. Downregulation of the PI3K/AKT survival pathway may result in the induction of cancer cell apoptosis and may decrease cancer cellular proliferation. IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by many cancer cell types, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been implicated in tumorigenesis and metastasis. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/cixutumumab)
Mechanisms of Action: IGF Inhibitor
Novel Mechanism: No
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Gliosarcoma|Sarcoma, Ewing|Primitive Neuroectodermal Tumors|Leiomyosarcoma|Peripheral Neuroectodermal Tumors, Primitive|Synovial Sarcoma|Rhabdomyosarcoma|Prostate Cancer|Hemangiosarcoma|Breast Cancer|Mesothelioma|Neuroendocrine Tumors|Osteosarcoma|Soft Tissue Cancer|Neuroblastoma|Embryonal Rhabdomyosarcoma|Embryonal Carcinoma|Wilms Tumor|Non-Small-Cell Lung Cancer|Neurofibrosarcoma|Alveolar Soft Part Sarcoma|Liposarcoma|Retinoblastoma|Uveal Melanoma|Alveolar Rhabdomyosarcoma|Peritoneal Cancer|Adenocarcinoma|Adrenocortical Carcinoma|Neuroendocrine Carcinoma|Hepatocellular Carcinoma|Hepatoblastoma|Kidney Cancer|Liver Cancer|Colorectal Cancer|Head and Neck Cancer|Squamous Cell Carcinoma|Pancreatic Cancer|Small Cell Lung Cancer|Male Breast Cancer|Esophageal Cancer|Large Cell Carcinoma|Gastrointestinal Cancer|Bronchiolo-Alveolar Adenocarcinoma
Phase 1: Neuroendocrine Tumors|Oncology Solid Tumor Unspecified|Neuroendocrine Carcinoma|Insulinoma|Peripheral Neuroectodermal Tumors, Primitive|Carcinoma, Merkel Cell|Medullary Carcinoma|Carcinoid Tumor|Islet Cell Carcinoma|Gastrinoma|Paraganglioma|Pancreatic Cancer|Glucagonoma|Malignant Carcinoid Syndrome|Carotid Body Tumor|Somatostatinoma|Gastrointestinal Cancer|Sarcoma, Ewing|Primitive Neuroectodermal Tumors|Pinealoma|Glioma|Thrombocytopenia|Hypertension|Neutropenia|Hyperglycemia|Anemia|Hepatocellular Carcinoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCI-2011-03039 | P2 |
Completed |
Head and Neck Cancer|Squamous Cell Carcinoma |
2018-08-15 |
|
| BATTLE-FL | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2017-08-15 |
|
| NCI-2011-01917 | P2 |
Completed |
Small Cell Lung Cancer |
2016-11-15 |
|
| 10-C-0146 | P2 |
Completed |
Mesothelioma|Peritoneal Cancer |
2016-08-13 |